Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline wins SMC recommendation for Revolade

GlaxoSmithKline wins SMC recommendation for Revolade

12th August 2010

GlaxoSmithKline has been granted a restricted recommendation for its chronic immune thrombocytopenic purpura (ITP) treatment Revolade to be used among patients in Scotland.

The Scottish Medicines Consortium (SMC) has endorsed the use of the drug among splenectomised and non-splenectomised patients with severe symptomatic ITP or a high risk of bleeding, based on positive data from clinical trials.

It means that Scotland becomes the first area in the UK where Revolade has been recommended as a cost-effective NHS treatment.

Dr Mark Drummond, consultant haematologist and honorary senior clinical lecturer at Gartnavel General Hospital, described this as "fantastic news" for sufferers of ITP, a condition for which there are few available treatment options.

He said Revolade "is relatively easy to take and offers a reduced risk of bleeding during treatment, something that we know worries patients and has an impact on their quality of life".

Earlier this week, GlaxoSmithKline published new clinical data on its new leukaemia drug Arzerra, demonstrating its safety and efficacy profile.ADNFCR-8000103-ID-800022330-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.